Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Argus Health
Chubb
Boehringer Ingelheim
Farmers Insurance
Julphar
Queensland Health
Teva
US Department of Justice

Generated: January 21, 2018

DrugPatentWatch Database Preview

ZYDELIG Drug Profile

« Back to Dashboard

When do Zydelig patents expire, and when can generic versions of Zydelig launch?

Zydelig is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are twelve patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty-four countries.

The generic ingredient in ZYDELIG is idelalisib. One supplier is listed for this compound. Additional details are available on the idelalisib profile page.
Summary for ZYDELIG
International Patents:148
US Patents:12
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 65
Clinical Trials: 8
Patent Applications: 91
Drug Prices:see details
DailyMed Link:ZYDELIG at DailyMed
Drug patent expirations by year for ZYDELIG
Pharmacology for ZYDELIG

US Patents and Regulatory Information for ZYDELIG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ZYDELIG

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,487,772 Inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
6,518,277 Inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
7,932,260 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,779,131 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,207,153 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
6,667,300 Inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,586,597 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,653,077 Inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,993,583 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
8,623,881 Inhibitors of human phosphatidylinositol 3-kinase delta ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZYDELIG

Supplementary Protection Certificates for ZYDELIG

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017004 Lithuania ➤ Subscribe PRODUCT NAME: IDELALISIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/938 20140918
2017 00007 Denmark ➤ Subscribe PRODUCT NAME: IDELALISIB; REG. NO/DATE: EU/1/14/938 20140924
0867 Netherlands ➤ Subscribe PRODUCT NAME: IDELALISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/938 20140919
2017000008 Germany ➤ Subscribe PRODUCT NAME: LDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 20140918
90006-9 Sweden ➤ Subscribe PRODUCT NAME: IDELALISIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/938 20140919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Argus Health
Mallinckrodt
Accenture
Chubb
US Department of Justice
Healthtrust
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot